The downregulation of one of these proteins, prohibitin, was confirmed in vivo in ovarian cancer tissues from patients resistant to platinum-based chemotherapy [120], implicating it as a prognostic novel biomarker of ovarian cancer chemoresistance. Here, PHB1 is linked to ovarian carcinoma.